Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426670 | 1.00 | LCK (0.41) | LCKFGFR4CYP17A1ATRRAB9A | |
| SCHEMBL18989702 | 0.87 | LCK (0.40) | LCKCYP17A1RAB9AMEN1NPC1 | |
| SCHEMBL30602604 | 0.86 | FGFR4 (0.41) | LCKFGFR4CYP17A1ATRRAB9A | |
| SCHEMBL29394473 | 0.86 | LCK (0.47) | LCKRAB9AMEN1NPC1GAA | |
| SCHEMBL23649610 | 0.83 | KDM4E (0.40) | LCKRAB9AMEN1NPC1GAA | |
| SCHEMBL31338383 | 0.82 | RAB9A (0.52) | RAB9AMEN1NPC1KMT2A | |
| SCHEMBL23666960 | 0.82 | HDAC3 (0.38) | LCKATRRAB9AMEN1NPC1 | |
| SCHEMBL29865217 | 0.82 | HDAC3 (0.38) | LCKATRRAB9AMEN1NPC1 | |
| SCHEMBL12710236 | 0.82 | LCK (0.42) | LCKCYP17A1ATRRAB9AMEN1 | |
| SCHEMBL19538278 | 0.81 | LCK (0.37) | LCKRAB9AMEN1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021262628-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-12-30 | — | — | WO | disclosed |
| US-20210403483-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-12-30 | — | — | US | disclosed |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-20190040073-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. | 2019-02-07 | — | — | US | disclosed |
| WO-2017189828-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | SCIFLUOR LIFE SCIENCES, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170313708-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | FELIQS CORPORATION (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403483-A1 | POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GAA, UGT2B7 | LCK 1808/4885FGFR4 380/4885CYP17A1 125/4885 |
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | LCK 4542/4885FGFR4 1687/4885CYP17A1 329/4885 |
| US-20200102331-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | LCK 4271/4885FGFR4 4402/4885CYP17A1 3582/4885 |
| US-20190040073-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | LCK 3359/4885FGFR4 232/4885CYP17A1 840/4885 |
| US-20170313708-A1 | NONANOIC AND DECANOIC ACID DERIVATIVES AND USES THEREOF | FFAR3, FFAR2, FFAR1 | LCK 3359/4885FGFR4 232/4885CYP17A1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.